Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target ...

In a report released today, Reni Benjamin from JMP Securities maintained a Hold rating on Allogene Therapeutics (ALLO – Research Report).

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

L Consolidation Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Continuing with Site Activation and Patient ...

Led by former Kite execs Arie Belldegrun and David Chang, Allogene partnered with French firms Cellectis and Servier to develop allogeneic CAR-Ts, after buying out Pfizer and taking over its role ...

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on ...

Bestselling author David Baldacci will be speaking on Nov. 18 at the Canton Palace Theatre as part of a Stark Library event. The prolific author will be releasing a new book in "The 6:20 Man ...

Actor Brad Pitt with director David Fincher on the set of the 1995 movie 'Se7en.' But first, a little background on the director. Born on Aug. 28, 1962, in Denver, Fincher always had an interest ...

Allogene Therapeutics (ALLO) is expected to deliver a year-over-year increase in earnings on flat revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for ...